IPO closed in February 2019
Hoth has exclusive worldwide rights to the BioLexa Platform.
Good day everyone,
Today we are initiating coverage of Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, focused on developing targeted therapeutics for eczema, dermatological and chronic wound disorders, psoriasis, acne and lupus.
Hoth operates as a company that develops drugs created by universities and others, under license, bringing them through clinical trials and commercializing them.
Developmental biopharma companies can see their share price explode with a significant catalyst. HOTH has several viable products in its pipeline and any one of them could generate such a catalyst.
Current price $6.65 per share
Outstanding shares (est.) 9.6 million shares
Float (est.) 3.86 million shares
52-week range $13.88 to $4.41 per share
Hoth closed its IPO on February 15th and is still largely under the radar of investors.
We believe Hoth is at the forefront of significant medical technology in areas with massive market potential and its shares may represent the potential for a ground floor opportunity.
Hoth has assembled a scientific advisory board that includes some of the nation’s top professionals in the field of dermatology.
The Hoth Development Pipeline:
Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. BioLexa™ is a combination of existing drugs that inhibit the formation of the biofilms that form around bacteria leaving the bacteria at the mercy of the immune system and antibiotics. These biofilms can make bacteria up to 1000 times more resistant to antibiotics.
BioLexa™ is being developed for the treatment of eczema and diabetic ulcers. The company is currently developing a Phase II clinical study. Hoth intends to pursue a 505 (B)(2) FDA designation for BioLexa™. On June 6th, HOTH announced the formation of an Australian subsidiary to further conduct its clinical trials.
The potential market for BioLexa™ indications exceeds $14 billion.
VNLG-152 is a drug exclusively licensed from University of Maryland, Baltimore, and has shown strong preclinical results for the treatment of psoriasis and acne patients. VNLG 152 has also shown strong pre-clinical data in cancer.
Another asset is an exclusive license from University of Cincinnati for a genetic marker that will help test a person’s propensity to suffer from food allergies and/or eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.
Recently, on May 14th, Hoth announced it intends to collaborate with Zylö Therapeutics Inc. to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Hoth is working toward impacting skin indications from the “inside out” instead of the current method of topical treatments.
As part of your due diligence we encourage you to visit the link below for more details about the company’s pipeline:
Hoth has a strong intellectual property portfolio, including exclusive licenses, patents and trademarks.
HOTH shares have a 52-week high of $13.38, indicating a potential gain over 100%.
The potential market for Hoth products is several billions of dollars.
Short interest in HOTH shares is virtually nil. (5-14-19)
As the chart indicates, HOTH shares have blasted past their 50 DMA of $5.50 and may be poised for a significant bounce.
The Traders News Group
We will be back with updates soon.
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated fifteen thousand dollars cash via bank wire by source 4 communications llc for this weeks mention of HOTH. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.